Omeros

News

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

Omeros seeks urgent FDA meeting after it rejects key drug

Shares in Omeros plummeted yesterday after the FDA rejected approval of its narsoplimab drug for a rare and life-threatening complication of haematopoietic stem cell transplants (HSCT), say

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Breakthrough status for nephropathy drug lifts Omeros

The FDA has given breakthrough therapy designation to OMS721, a new treatment for the

News

Rival to rare disease blockbuster Soliris moves ahead

Seattle-based biotech firm Omeros says its pipeline treatment to rival Alexion's Soliris is set to enter phase 3 later this year.

Novo builds pipeline again with $2.1bn Omeros deal

Omeros seeks urgent FDA meeting after it rejects key drug

Breakthrough status for nephropathy drug lifts Omeros

Rival to rare disease blockbuster Soliris moves ahead

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Omeros

Editor's Picks